These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2921090)

  • 1. Tobramycin dosage recommendation in patients with cystic fibrosis.
    Davis RL; Mendelman P; Ramsey B; Smith AL
    Infection; 1989; 17(1):41. PubMed ID: 2921090
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis.
    Touw DJ; Vinks AA; Heijerman HG; Bakker W
    Ther Drug Monit; 1993 Feb; 15(1):52-9. PubMed ID: 8451782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of infusion method on serum tobramycin concentrations in adults with cystic fibrosis.
    Pleasants RA; Williams DM; Waltner WE; Knowles MR
    Clin Pharm; 1990 Jul; 9(7):541-5. PubMed ID: 2376111
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of tobramycin in cystic fibrosis.
    Kelly HB; Menendez R; Fan L; Murphy S
    J Pediatr; 1982 Feb; 100(2):318-21. PubMed ID: 7057342
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.
    Winnie GB; Cooper JA; Witson J; Cowan RG; Mayer D; Lepow M
    Pediatr Infect Dis J; 1991 May; 10(5):381-6. PubMed ID: 1906161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosage of tobramycin in cystic fibrosis--a short report.
    Chrystyn H; Alexander JM
    J Clin Hosp Pharm; 1985 Jun; 10(2):219-20. PubMed ID: 4019795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of cystic fibrosis--step by step.
    Hazinski TA
    J Pediatr; 2001 Oct; 139(4):3A. PubMed ID: 11598588
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval.
    Horrevorts AM; Degener JE; Dzoljic-Danilovic G; Michel MF; Kerrebijn KF; Driessen O; Hermans J
    Chest; 1985 Aug; 88(2):260-4. PubMed ID: 4017681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
    Stenbit AE; Bullington WM; Heh JL; Flume PA
    J Cyst Fibros; 2013 Jul; 12(4):403-6. PubMed ID: 23266092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of clinical pharmacokinetic services provided to children and adolescents with cystic fibrosis.
    Kearns GL; Jiménez JF; Brown AL; Warren RH
    J Ark Med Soc; 1985 Oct; 82(5):215-9. PubMed ID: 2933385
    [No Abstract]   [Full Text] [Related]  

  • 12. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
    Horrevorts AM; de Witte J; Degener JE; Dzoljic-Danilovic G; Hop WC; Driessen O; Michel MF; Kerrebijn KF
    Chest; 1987 Nov; 92(5):844-8. PubMed ID: 3665599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling.
    Jones A; Beisty J; McKenna D; Clough D; Webb K; Morris J; Keevil B
    Eur Respir J; 2012 Jun; 39(6):1537-8. PubMed ID: 22654009
    [No Abstract]   [Full Text] [Related]  

  • 14. Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.
    Braccini G; Lori I; Neri AS; Festini F; Pela I; Ciuti R; Boni V; Zavataro L; Braggion C; De Martino M; Taccetti G
    J Chemother; 2009 Feb; 21(1):101-4. PubMed ID: 19297282
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis.
    Mukhopadhyay S; Baer S; Blanshard J; Coleman M; Carswell F
    J Antimicrob Chemother; 1993 Mar; 31(3):429-36. PubMed ID: 8486576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
    Hennig S; Holthouse F; Staatz CE
    Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients.
    Guglielmo BJ; Quan LA; Stulbarg MS
    J Antimicrob Chemother; 1996 May; 37(5):1040-2. PubMed ID: 8737161
    [No Abstract]   [Full Text] [Related]  

  • 19. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
    McCrae WM; Raeburn JA; Hanson EJ
    J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.